CONVERGENT DIAGNOSTICS LLC NPI 1558808204

NPI Details

CONVERGENT DIAGNOSTICS, LLC is a clinical medical laboratory in Allen, TX. The provider is (1) A clinical laboratory is a facility for the biological, microbiological, serological, chemical, immunohematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, human beings. These examinations also include procedures to determine, measure, or otherwise describe the presence or absence of various substances or organisms in the body. Facilities only collecting or preparing specimens (or both) or only serving as a mailing service and not performing testing are not considered clinical laboratories. (2) Any facility that examines materials from the human body for purposes of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of, the health of human beings. Typical divisions of a clinical laboratory include hematology, cytology, bacteriology, histology, biochemistry, medical toxicology, and serology. CONVERGENT DIAGNOSTICS, LLC NPI is 1558808204. The provider is registered as an organization entity type.

The provider's business location address is:

718 S GREENVILLE AVE STE 100
ALLEN, TX
ZIP 75002-319
Phone: (214) 501-5171

The provider's authorized official is Marc Ingram .
The authorized official title is Ceo and has the following contact phone number (214) 501-5171.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Detection test by nucleic acid for organism, amplified probe technique (HCPCS:87798)
• Detection test for candida species (yeast), amplified probe technique (HCPCS:87481)
• Special stained specimen slides to identify organisms including interpretation and report (HCPCS:88312)
• Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique (HCPCS:87641)
• Cell examination of urine, manual (HCPCS:88120)
• Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique (HCPCS:87651)
• Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique (HCPCS:87653)
• Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique (HCPCS:87500)
• Detection test by nucleic acid for herpes simplex virus, amplified probe technique (HCPCS:87529)
• Detection of mycoplasma genitalium by dna or rna probe (HCPCS:87563)
• Infectious agent drug susceptibility analysis (HCPCS:87900)
• Detection test for gardnerella vaginalis (bacteria), amplified probe technique (HCPCS:87511)
• Testing for presence of drug, by chemistry analyzers (HCPCS:80307)
• Cell examination of body fluid, smears (HCPCS:88104)
• Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique (HCPCS:87491)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0481)
• Pathology examination of tissue using a microscope, intermediate complexity (HCPCS:88305)
• Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique (HCPCS:87661)
• Detection test by nucleic acid for human papillomavirus (hpv), high-risk types (HCPCS:87624)
• Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique (HCPCS:87591)
• Preparation of tissue for examination by removing any calcium present (HCPCS:88311)
• Special stained specimen slides to examine tissue including interpretation and report (HCPCS:88313)
• Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus (HCPCS:87637)
• Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique (HCPCS:87581)
• Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique (HCPCS:87486)
• Detection test by nucleic acid for legionella pneumophila (water borne bacteria), amplified probe technique (HCPCS:87541)
• Detection test by nucleic acid for mycobacteria species (bacteria), amplified probe technique (HCPCS:87551)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0003)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within (HCPCS:U0005)
• Detection test by nucleic acid for mycobacteria avium-intracellulare (bacteria), amplified probe technique (HCPCS:87561)
• Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure (HCPCS:88377)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0480)
• Special stained specimen slides to examine tissue, initial procedure (HCPCS:88342)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0482)
• Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv) (HCPCS:0500T)
• Detection test by nucleic acid for mycobacteria tuberculosis (tb bacteria), amplified probe technique (HCPCS:87556)
• Urinalysis for bacteria (HCPCS:81007)
• Manual urinalysis test with examination using microscope, automated (HCPCS:81001)
• Screening examination of specimen cells, screening and interpretation (HCPCS:88160)
• Detection test by nucleic acid for cytomegalovirus, quantification (HCPCS:87497)
• Detection by nucleic acid bartonella henselae and bartonella quintana (bacteria), amplified probe technique (HCPCS:87471)
• Detection test by nucleic acid for cytomegalovirus (cmv), amplified probe technique (HCPCS:87496)
• Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision (HCPCS:G0123)
• Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method (HCPCS:G0416)
• Pap test, manual screening (HCPCS:88142)
• Cell examination of specimen, selective cellular enhancement technique (HCPCS:88112)
• Analysis of urine, except immunoassays (HCPCS:81005)

The enumeration date for this NPI number is 1/19/2017 and was last updated on 4/17/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: